leadf
logo-loader
viewCellular Goods PLC
(
LSE:CBXFRA:6XS
)

Cellular Goods: A unique and innovative approach to CBD focused on delivering premium consumer products

Snapshot

  • Cellular Goods inks supply deal for ingestible products
  • Aiming high: how to make investment choices in the cannabis world
  • Cellular Goods signs multi-year manufacture and supply agreement for ingestible products
Cellular Goods PLC -

Quick facts: Cellular Goods PLC

Follow
LSE:CBX

Price: 5.6 GBX

Market Cap: £28.27 m

About the company

We are a UK-based premium consumer brand serving the skincare and sports recovery markets. Our products are formulated with lab-made, approved and high-quality cannabinoids. Harmonising nature with science, our formulations work in symbiosis with the body. Because our cannabinoids are biosynthetic they are always pesticide-free, legal, not animal-tested and more sustainable than those derived from plants. The company is headquartered in London and listed on the main market of the London Stock Exchange. Please visit www.cellulargoods.co

How it is doing

16 Aug 2021

Cellular Goods PLC (LSE:CBX, FRA:6XS) said it has signed a multi-year manufacture and supply agreement with Chanelle McCoy Health Ltd (CMH) to bring forward the launch of a range of clinically validated ingestible products to the fourth quarter of 2021.

Under the deal, CMH, a developer of high-quality ultra-pure cannabinoid (CBD) products, will initially supply three CBD ingestibles which will go on sale under the Cellular Goods brand in the UK, followed by continental Europe in 2022.

Cellular Goods said the agreement marks a “significant step” for its go-to-market strategy and will accelerate its entry into the market for ingestible wellness products by more than a year.

The firm added that key benefits of the deal include an immediate entry into the most developed market segment with early revenue generation opportunity, an expansion of its branded product range into a complementary market segment, access to a range of novel-food regulation-compliant products which are ready for launch, reduced upfront research & development expenditure and the opportunity for future product development and research collaborations through its access to ultra-pure CBD and pharmaceutical expertise.

10 Jun 2021

Cellular Goods PLC (LON:CBX) signed a multi-year supply agreement for cannabigerol (CBG) with Toronto-listed Willow Biosciences.

Willow will supply Cellular Goods with its proprietary, ultra-pure, biosynthetically produced, cannabigerol to be used in Cellular Goods' premium cannabinoid-based skincare products which will be launched in the autumn of 2021.

25 May 2021

Cellular Goods PLC (LON:CBX), the maker of lab-made cannabinoid products backed by David Beckham, said it is on track to roll out its first consumer product range in Autumn this year followed by a ‘movement’ product range for the after-sport recovery market next Spring.

In an outlook statement accompanying its half-year results, the company said it is looking to the future “with confidence” amid growing public acceptance and scientific validation of the benefits of cannabinoids.

Insight: Aiming high: how to make investment choices in the cannabis world

18 Mar 2021

Picking stocks in the cannabis space can be a daunting task, but what once used to be a very ‘out there’ sector is now whetting the appetite of investors.

It all started in 2018, when Canada legalised recreational use, but the UK is becoming an increasingly fertile ground for the sector after the FCA allowed medicinal cannabis companies to list in London last September.

What management says

16 Aug 2021

Cellular Goods PLC (LSE:CBX, FRA:6XS)'s (LON:CBX) Alexis Abraham talks to Proactive London's Katie Pilbeam about signing a multi-year manufacture and supply agreement with Chanelle McCoy Health Ltd (CMH). 

As Abraham explains 'we identified an opportunity with a company that very much shared our values' to bring forward the launch of a range of clinically validated ingestible products to the fourth quarter of 2021.

The deal will introduce consumers to novel food compliant CBD ingestibles that Abraham believes will complement their CBG skincare range.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Tiziana Life Sciences: A different approach, tackling disease using a safe,...

Tiziana Life Sciences (NASDAQ:TLSA) (LON:TILS)'s investment case is presented by Proactive Research Analyst John Savin who takes viewers through their activities and timeline of progress to come.  The firm deliver its fully human therapeutic antibody, foralumab, to the gut or nose mucosal...

1 day, 13 hours ago

6 min read